AbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as climbing oil, yields amplify inflation fears
- Oil jumps 5%, then pares gains after Trump says no attack on Iran this month
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
| AbbVie (NYSE: ABBV) | Delayed: 269.20 -2.16 (0.8%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $271.36 | 52 Week High | $68.12 | |||
| Open | $270.98 | 52 Week Low | $50.71 | |||
| Day High | $271.61 | P/E | 58.39 | |||
| Day Low | $265.71 | EPS | $4.61 | |||
| Volume | 1,804,218 | |||||
